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Annual direct costs were calculated (by third-party payer perspective) for privately-
insured (n  4,764) and Medicare (n  48,742; medical costs only) beneﬁ ciaries. Indi-
rect costs were calculated for privately-insured employees with disability data (n 
1148). Costs were reported in 2006 dollars. RESULTS: In Medicare, mean medical
costs per non-vertebral, non-hip (NVNH) fracture patient were $7,463 in excess of 
controls ($13,720 vs. $6,258; p  0.01).The most expensive patients had fractures of 
the hip, multiple sites, and femur (excess costs of $25,120; $20,049; $19,213, respec-
tively). Aggregate annual excess medical costs of these NVNH patients (n  35,933)
were $268.1 million versus $200.9 million for hip fracture patients (n  7,997)
(excludes patients with hip and NVNH on index date). In the privately-insured popu-
lation, excess mean direct costs per NVNH fracture patient were $5,381 ($11,090 vs.
$5,709; p  0.01). The most expensive patients had fractures of the hip, multiple sites, 
and pelvis (excess costs of $13,801; $9,642; and $8,164, respectively). Aggregate
annual excess direct costs of these NVNH patients (n  4478) were $24.1 million 
versus $3.5 million for hip fracture patients (n  255). Mean excess indirect costs per
NV employee were $1956 ($4,349 vs. $2393; p  0.01). CONCLUSIONS: Excess 
direct and indirect costs of NV osteoporotic fracture patients to payers are substantial.
While hip fracture patients are more costly per patient, NVNH fracture patients are
associated with a larger percentage of fractures and aggregate excess costs for both 
these privately-insured and Medicare samples.
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GOLIMUMAB SIGNIFICANTLY REDUCES TIME LOST
FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: 
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OBJECTIVES: To evaluate the effect of golimumab (GLM) on time lost from work 
in patients with rheumatoid arthritis (RA). METHODS: The effect of GLM on time 
lost from work (days) was prospectively evaluated in 3 multicenter, randomized,
double-blind, placebo-controlled studies in patients with RA. Pooled data from 
patients receiving any injection of study agent (GLM or placebo) with or without 
methotrexate (MTX) in 3 RA studies (GO-BEFORE, GO-FORWARD, and GO-
AFTER) were included. GLM SC injections of 50 or 100 mg were administered q4 
weeks. Time lost from work for patients was collected through a questionnaire at 
baseline and q8 weeks through week 24 and was summarized cumulatively through 
week 24 with comparisons between groups using ANOVA on van der Waerden normal 
scores. The proportion of patients reporting no time lost from work in the GLM /
MTX group was compared with the PBO / MTX group using the chi square test.
RESULTS: Through week 24, signiﬁ cant differences in time lost from work were 
observed between the GLM / MTX group and the PBO / MTX group. At week 
24, the PBO / MTX group lost 6.9 o 19.7 days compared with 5.0 o 19.4 days for
the combined GLM /MTX group. At week 24, the 75th percentile for the combined 
GLM /MTX group was 1.000 day (range 0–180) compared with 3.000 days (range
0–120) for the PBO / MTX group. A signiﬁ cantly higher proportion of patients in 
the combined GLM / MTX group reported no time lost from work compared with
the PBO / MTX group (73.1% vs. 60.7%; p  0.002). CONCLUSIONS: GLM /
MTX signiﬁ cantly reduced time lost from work for patients with RA compared with 
PBO / MTX.
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THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: 
ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
2005 AND 2006 DATA
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OBJECTIVES: Previous research reported the prevalence and health care and
productivity cost of rheumatoid arthritis (RA) using Medical Expenditure Panel
Survey (MEPS) 2004 data; this study replicates the analyses using 2005 and 2006 
data. METHODS: MEPS, a comprehensive survey of approximately 35,000 individu-
als in the US, was used to identify non-institutionalized US persons with RA. Multiple 
linear and semi-log regressions were applied to estimate total annual health care
expenditure and income (yearly wages) associated with RA. Covariates in the expen-
diture equations included demography, comorbidities, and overall health status.
Semi-log regression for income renders the distribution of income symmetric. Covari-
ates in the income equations included demography, comorbidities, education, occupa-
tion, and health status. RESULTS: A total of 150 and 148 patients with RA were 
identiﬁ ed in 2005 and 2006 versus 136 in 2004; 75% (2005) and 80% (2006) were 
women versus 76% (2004), and 53% (2005) and 50% (2006) of RA patients 
were between the ages 41–64 years versus 56% in 2004. Linear regressions demon-
strated that the incremental increase in health care cost associated with RA was
$2902 (P  0.0001) in 2005 and $1882 (P  0.003) in 2006, versus $4422 (2004). 
Semi-logarithmic regression explaining wages in 2005 and 2006 had adjusted R2 of 
56% and 59%. RA signiﬁ cantly reduced wages by $2207 (0.9237 log estimate)
annually (P  0.0001) in 2005 and $1,559 (0.5038 log estimate; P  0.05) in 2006; 
wages of RA patients in 2004 were reduced by $3526 (1.088 log estimate). CON-
CLUSIONS: The economic impact of RA is substantial to both income loss and health 
care costs. Replication and validation of outcomes research are important to establish
the precision of statistical associations as well as changes across time. Further study
will explore whether changes in the care of patients with RA affect changes in out-
comes over time.
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OBJECTIVES: Fibromyalgia syndrome (FMS) is a chronic disorder deﬁ ned by wide-
spread musculo-skeletal pain that is often associated with a number of comorbidities 
including fatigue, sleep disturbance, stiffness and functional limitation. In absence of 
a speciﬁ c diagnostic test, FMS is typically difﬁ cult to identify, and there is limited 
knowledge about the economic burden of FMS. The objectives of this study were to
estimate prevalence of comorbidities, health care resources utilization and costs associ-
ated with FMS. METHODS: A retrospective cohort study was conducted using data 
from the Quebec provincial health plan (RAMQ) for a random sample of patients
with two or more recorded diagnoses of FMS and a control cohort without FMS,
matched for age and gender, for a period spanning from June 2006 to July 2007. 
Prevalence of comorbidities was estimated and a chronic disease score was calculated.
Health care resources consumed by FMS and non-FMS patients included visits to 
physicians, physician’s interventions, pain-related medications, non-pain-related medi-
cations and hospitalizations. RESULTS: A total of 16,010 FMS patients were identi-
ﬁ ed, with a matched number of control patients. The mean age of the study population 
was 58.8 years and most subjects were women (67.8%). The prevalence of most
comorbidities and the chronic disease score were signiﬁ cantly greater in the FMS 
patients than in control group (3.8 vs. 2.8; p  0.001). Health resources utilization
during the study period was signiﬁ cantly greater among FMS patients than non-FMS 
patients: the annual number of physician visits and interventions was 25.1 for FMS
vs. 14.8 for non-FMS patients. The amount paid by the RAMQ was signiﬁ cantly
greater for patients with FMS ($4065) compared to patients without FMS ($2766, 
p  0.001). CONCLUSIONS: This analysis of the RAMQ database indicated that
comorbidities are highly prevalent in FMS patients, and suggested that the economic 
burden associated with FMS is substantial.
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OBJECTIVES: To evaluate the relationship between out-of-pocket (OOP) pharmacy
expenses and switching rates among anti-tumor necrosis factor (anti-TNF) agents in 
patients with rheumatoid arthritis (RA). METHODS: This retrospective study utilized 
claims for RA patients from the PharMetrics Patient Centric database. The index 
biologic date was deﬁ ned as the ﬁ rst anti-TNF claim between January 1, 2000 and 
December 31, 2006. A minimum of 30 months of continuous plan eligibility was 
required: 6 months prior to and 24 months following the index biologic date. Patients
were followed for 24 months after the index biologic date. Switching among anti-
TNFs (inﬂ iximab, etanercept, or adalimumab) was recorded. The pharmacy OOP 
expense was deﬁ ned as the allowed amount minus amount paid. The annual OOP of 
$500 was used as a cut point to deﬁ ne the high and low OOP groups. RESULTS: A
total of 3,086 patients were analyzed (74.5% female; mean age  49.9 years). Half 
(1597; 51.7%) had an annual pharmacy OOP $500. The mean and median annual 
OOP expenses for the study population were $929 and $528, respectively. During the 
study period, 465 (15.1%) patients switched to a different anti-TNF agent. Compared 
to the lower OOP expense group, patients in the higher OOP group had a higher 
switching rate (18.0% versus 12.0%, p  0.0001), and shorter time to switch (329
days versus 352 days, p  0.230). In the logistic regression, after controlling for age, 
gender, co-morbidity, and disease staging, patients in the high OOP group had signiﬁ -
cantly higher switching rate (odds ratio 1.60, 95% conﬁ dence interval 1.30–1.96).
CONCLUSIONS: Higher OOP expenses were associated with higher rates of switch-
ing among the anti-TNF agents in the RA patient population. Decision makers may 
consider such ﬁ ndings in the beneﬁ t design of this therapeutic class.
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OBJECTIVES: The purpose of this study was to estimate the expected medical cost
of a single conservative medical management (CMM) per patient with osteoporotic 
vertebral compression fracture (VCF) in Japan. METHODS: A questionnaire survey
was conducted for Japanese orthopedic surgeons who mainly provide CMM for 
patients with VCF during their daily clinical practices, and who consented to
participating in the survey. Responses to the questionnaire were summarized and
the expected medical costs for each therapeutic regimen until recovery per patient
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were calculated for each treatment strategy and severity level. Four types of items 
were surveyed: treatment strategy for VCF (A.hospitalization only, B.hospitalization 
to outpatient, C.outpatient visit only, D.operation, E.follow-up only, F.other), treat-
ment period of each VCF therapy (length of stay and outpatient visit), examination
items (diagnostic imaging, laboratory test) and therapeutic regimens (use of cast or 
hard/soft corset, rehabilitation, nerve block, medication). Severity of VCF was classi-
ﬁ ed into three levels: status1(lumbar back pain;/ADL impairment;-/neurological 
symptoms;-), status2(//), status3(//). RESULTS: The questionnaire was 
addressed to 83 institutions, and responses from 68 (response rate 82%) were received. 
Of these, 65 responses were available for estimation. When considering the propor-
tions of treatment strategies (A to C), the expected medical costs for each status were: 
status1; US$1637, status2; US$4485 and status3; US$7962 (1US$  92JPY). The 
expected medical cost of CMM for a patient with osteoporotic VCF in Japan was 
estimated at US$4,032, and the total annual costs of CMM for VCF on a national 
scale were estimated to be US$1.18 billion. CONCLUSIONS: Japan being an aging 
society, the burden of illness for VCF is a signiﬁ cant issue. Further standardization
and customization of treatment modalities are expected for optimal allocation of 
medical resources.
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AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS
OF RITUXIMAB AND ABATACEPT IN THE TREATMENT OF MODERATE
TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE
RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA
Yunger S, Mistry B
Hoffmann-La Roche, Mississauga, ON, Canada
OBJECTIVES: Rituximab (RTX) and abatacept (ABAT) are novel therapies to treat 
moderate to severe Rheumatoid Arthritis (RA). This analysis was conducted to evalu-
ate the cost-effectiveness of these two therapies in patients with active RA who have
had an inadequate response to anti-tumour necrosis factor (TNF) inhibitor therapies 
from the Ontario Ministry of Health perspective. METHODS: A cost-utility model
was used to evaluate the direct costs and outcomes of a standard Canadian treatment
sequence in the absence and presence of either RTX  methotrexate (MTX) or ABAT
 MTX after failure of one anti-TNF. The model simulated 10,000 RA patients over 
a life time. RTX and ABAT were evaluated against the following standard Canadian
treatment sequence after failure of one anti-TNF (etanercept): adalimumab  MTX, 
inﬂ iximab  MTX, leﬂ unomide, gold, cyclosporine and palliative care. Baseline char-
acteristics from REFLEX (Randomized Evaluation of Long-term Efﬁ cacy of Rituximab 
in RA) clinical trial were: mean age, 52.2 years; mean HAQ score, 1.88. ACR response 
rates from RCTs were placebo-adjusted to minimize bias from cross-trial comparisons. 
All relevant direct costs were included in the model including drug costs, administra-
tion and monitoring, and adverse events. Observational data were used to estimate
long-term HAQ progression and average time on treatment for patients responding
to therapy. Costs and beneﬁ ts were discounted at 5% per annum. RESULTS: The 
introduction of RTX following failure of one biologic resulted in a gain of 0.443 
QALYs at an additional total cost of $3710 resulting in an ICER of $8380/QALY. 
The introduction of ABAT following failure of one biologic resulted in a gain of 0.387
QALYs at an additional total cost of $18,588 resulting in an ICER of $48,000/QALY.
CONCLUSIONS: Rituximab is economically attractive from a Canadian payer per-
spective and is a cost effective treatment option over abatacept when compared in the
studied population.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported
Outcomes Studies
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IMPACT OF A SUPPORT PROGRAM ON THE TREATMENT COMPLIANCE
IN OSTEOPOROSIS PATIENTS
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OBJECTIVES: To assess the extension in which the participation of a patient in a
support program contributes with increased osteoporosis treatment compliance. Trials 
demonstrated that the compliance rates to oral bisphosphonates therapy present a 
signiﬁ cant drop along the ﬁ rst year of treatment and continue declining year after year.
The objective of a support program is to provide patient’s support providing informa-
tion about the disease, to interchange experiences with other patients, provide high 
calcium content nutrition tips and proper physical activities. METHODS: Quantita-
tive study conducted through personal and individual interviews using a structured
questionnaire. Two hundred and twenty interviews were conducted with female 
patients that concluded the bisphosphonate treatment, divided in two groups: one 
hundred-two registered and one hundred and eighteen non-registered into a support
program. RESULTS: The average treatment period with bisphosphonate between the
patients registered in the program is of 11 months vs. 4 months for non-registered
patients. The main causes of impact on the continuous use of bisphosphonate of the
patients non-registered in a support program include the treatment side effects (28% 
vs. 11%; p  0.002). From the total of patients interrupting the intake of bisphospho-
nate due to side effects the largest number are due to gastric problems. However, the
patients registered in a support program reach the treatment ﬁ nal (34% vs. 15%; 
p  0.01). CONCLUSIONS: The patients registered in a support program present the
tendency to follow the prescription and remain for a longer time period in the therapy. 
It is perceived that when the patients has access to wider information about the disease, 
which is one of the main objectives of a treatment support program, the therapy dis-
continuation rate due to side effects is lower. Because the patients are aware about 
the occurrence of gastric issues, they properly follow the guidelines, avoiding them
and reaching the treatment ﬁ nal.
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QUALITY OF LIFE AND COMPLIANCE IN GIRLS WITH
ADOLESCENT IDIOPATHIC SCOLIOSIS
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OBJECTIVES: The Brace Questionnaire (BrQ) is a recently-developed, condition-
speciﬁ c tool used to measure quality of life (QoL) in subjects treated with spinal 
bracing. While corrective bracing for adolescent idiopathic scoliosis (AIS) has more 
favourable outcomes when patients are compliant, one must appreciate that bracing
itself may be a stressful and traumatic experience, and compliance with a bracing
protocol is likely to be dependent upon patients’ physical, emotional and social well-
being. Using the BrQ we sought to explore relationships between QoL and compliance
with treatment. METHODS: The BrQ was administered to 31 AIS patients after 
a minimum of 1 year of wearing a brace for 1 year. Subjects were 13–16 year-old 
girls with signiﬁ cant deformity (Cobb angles 25–40 degrees). Participants were
divided into two groups according to their level of compliance with the bracing 
protocol. BrQ sub- and total scores were compared between the two groups using the 
t-test for comparison of means. RESULTS: Twenty participants were classiﬁ ed as 
compliant and 11 as non-compliant. Mean total BrQ scores (expressed as %) were 
83.7 for the compliant group and 64.4 for the non-compliant group (p  0.001). The 
compliant group scored signiﬁ cantly higher in six of the eight domains that make 
up the BrQ. Compliant patients had greater vitality and self esteem, and functioned
better in those domains covering physical, emotional and social performance. 
CONCLUSIONS: Poor QoL adversely affects compliance in AIS patients requiring
a brace. Non-compliant patients lack vitality and self esteem, and function poorly 
in the physical, emotional and social domains. Quality of life for adolescents with
idiopathic scoliosis may relate more to psychosocial coping mechanisms than to physi-
cal deformity and its consequences. It is important for remedial programmes to con-
sider personal, peer and family issues as part of improving QoL, promoting compliance 
and correcting deformity.
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PATIENTS SUCCESS CRITERIA AND EXPECTATIONS IN FALLS 
REHABILITATION
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OBJECTIVES: Performance-based instruments commonly used in clinical settings 
often do not capture important aspects of the patient’s health experience. Therefore, 
the primary aim of this study was to use a patient-reported outcomes (PRO) question-
naire to investigate patient’s success criteria and expectations when receiving rehabili-
tation services related to falls. METHODS: A group of patients (N  50, age  55) 
receiving physical therapy services were enrolled. Inclusion criteria consisted of: com-
munity dwellers with a history of falling, ability to walk 20 ft, and Mini-Mental State
Exam score 24. The Patient’s Perspective Outcome Questionnaire (PPOQ) was
administered at the initial physical therapy evaluation. PPOQ assesses current levels,
success criteria and expected levels for a number of health domains including: mobility,
self-care, interactions with people, community/social life, energy/drive, mental func-
tion, emotional distress, sensory function, and pain. A 100-point scale is used to assess
levels of interference across domains (0  not affected and 100  most affected).
RESULTS: Participants reported highest scores in the energy/drive (53), mobility (47),
and pain (44) domains. Interactions with people (21) and community/social life (31) 
received the lowest scores, suggesting that domains with a strong social component
were not as affected as domains with a strong physical component. Participants 
required signiﬁ cant improvement to consider their treatment successful. The mobility 
and energy/drive domains required signiﬁ cantly larger reductions than the community/
social life, and interactions with people domains (P  0.006). Across all domains, 
participant’s expectation was that the treatment would not meet their success criteria,
indicating that residual levels of impairment were expected after treatment. CONCLU-
SIONS: The results of this study point out that a number of health domains are sig-
niﬁ cantly affected in this population. These patients have treatment expectations that
exceed the mobility problems for which they were treated. In exploring meaningful 
change, the patient’s expectations and success criteria must be considered.
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OBJECTIVES: To assess symptoms, functionality, quality of life (QoL), and work/ 
productivity loss in Rheumatoid Arthritis (RA) patients treated with subcutaneous 
(SC) biologics. METHODS: Patient-reported data from the 2007 Rheumatoid Arthri-
tis Patient Study were analyzed. Symptoms were measured by morning stiffness,
fatigue, and pain scores deﬁ ned on a scale from 0 (no symptom) to 10 (severe
